CIT expands US presence
Appoints vice-president of business development North America
The company has appointed Bernard Galat as vice-president, business development, North America, who will be based in the Boston office.
The US represents 15% of CIT’s current sales; the aim is to increase this to 30% in three to five years.
Prior to joining CIT, Galat held senior sales and marketing positions with Xceleron, Parexel and Carestat.
‘This is an exciting time to be joining CIT as we expand the availability of our services in monoclonal antibody therapies, tissue cross-reactivity, functional genomics, safety pharmacology and carcinogenicity, including transgenic models,’ he said.
You may also like
Research & Development
Applied Biopharm Consulting awarded Innovation funding to validate AI-powered AAV vector engineering platform
Irish biotech consultancy Applied Biopharm Consulting has secured an Innovation Voucher from the Local Enterprise Office Cork North & West to collaborate with an academic partner in validating its computational platform for adeno-associated virus vector optimisation through laboratory testing